Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
4 hedge funds and large institutions have $29K invested in Northwest Biotherapeutics, Inc. Common stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
123% more capital invested
Capital invested by funds: $13K → $29K (+$16K)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Seelaus Asset Management
Chatham,
New Jersey
|
+$13K |
| 2 |
WPP
Whalerock Point Partners
Providence,
Rhode Island
|
+$2.67K |
Top Sellers
NWBO Hedge Fund Activity: Q1 2018 in Review
4 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2018, worth a combined $29K — up 123% from $13K a quarter earlier.
Fund positioning in NWBO was balanced in Q1 2018: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Seelaus Asset Management, opening a new position worth an estimated $13K.
- 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2018, unchanged from Q4 2017.
- Funds reported $29K of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2018, up 123% quarter-over-quarter.
- 1 fund opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2018 and 1 closed out, a net change of 0 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2018 was Seelaus Asset Management, an estimated $13K added.
Based on aggregated 13F filings for Q1 2018.